BioWorld

Jan. 18, 2002

View Archived Issues

Bush’s Bioethics Panel Meets For First Time, Starts On Cloning

Lactase Enzyme Mutant Gene Against Lactose Intolerance Discovered In Intestinal Cells

Maxim Begins Ceplene Phase III With Liver Metastases Patients

Holiday Notice

Other News To Note

Rigel Raises $31.5M To Move First Product Into Clinic In 2002

President’s Council on Bioethics

Cubist Meeting With FDA After Cidecin Fails To Meet Endpoint

Cubist Pharmaceuticals Inc. said its investigational antibiotic, Cidecin, failed to meet its primary endpoint in the first of two pivotal Phase III trials for community-acquired pneumonia. Read More

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...

Neutrophils put the brakes on fat loss

BioWorld Science

Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...

Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints

BioWorld

Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...